Jump to:
Mike Tentilucci joined Ropes & Gray's corporate department in 2021. Mike focuses his practice on representing public companies and investment banks in connection with capital markets transactions and compliance with securities laws and stock exchange rules and regulations, as well as mergers & acquisitions, other strategic transactions and general corporate governance matters.
Experience
Mike has represented:
- the lead underwriters in the $308 million initial public offering and $488 million follow-on offering of Loar Holdings Inc.
- the lead underwriters in follow-on equity offerings totaling $1.1 billion for Madrigal Pharmaceuticals, Inc.
- the selling shareholders including affiliates of TPG Capital, Leonard Green & Partners and Partners Group in Life Time Fitness’s secondary public offering valued at $699 million.
- Avista Healthcare Partners in its purchase of $130 million of convertible preferred stock of Organogenesis Holdings Inc.
- Novalis LifeSciences in its PIPE investment in Telesis Bio.
- Arbor Biotechnologies in its $73.9 million Series C financing.
- Acceleron Pharma Inc. in its sale to Merck.
- Pfizer Inc. in its acquisition of Trillium Therapeutics.
- the lead underwriters in the initial public offering of byNordic Acquisition Corporation.
- the lead underwriters in the initial public offering of CIIG Capital Partners II, Inc.
- the lead underwriters in the initial public offering of Tio Tech A.
- Novavax, Inc. in equity offerings and disclosure and governance matters.
- Cyteir Therapeutics, Inc. in its $133.2 million initial public offering and disclosure and governance matters.
- RVL Pharmaceuticals plc in equity offerings and disclosure and governance matters.
- an investment manager in the Series B financing for Breeze Aviation Group, Inc.
- TransMedics Group, Inc. in its acquisition of organ support and heart preservation transport system assets from Bridge to Life Ltd.